Breakthrough Device Medicare Coverage

Summary#

The bill creates a new “breakthrough device” designation and a 4-year transitional Medicare coverage period for such devices. It sets rules for when Medicare will pay for a designated breakthrough device during that transition, requires faster review of coverage requests, and gives $10 million per year to the Centers for Medicare & Medicaid Services (CMS) to carry out the changes. The broad goal is to speed Medicare patient access to medical devices that received priority review from the Food and Drug Administration (FDA).

Key changes:

• Creates a new statutory definition and designation process for “breakthrough devices.” Manufacturers may apply and the Secretary must decide within 6 months.
• Establishes a 4-year “transitional coverage period” starting on the designation date for each device.
• During that period, Medicare will cover a breakthrough device only when it is furnished according to FDA-approved labeling and for the indication that received priority review, and provided the device does not present undue risk of harm that outweighs potential benefits.
• Requires CMS to make a final national coverage decision (NCD) on a breakthrough device request before the end of the 4-year transitional period if the request is filed in time.
• Appropriates $10 million per year (FY2025–2030) to CMS’s Program Management Account to support these changes.

What it means for you#

• Medicare patients

  • May get faster access to certain new medical devices that the FDA gave priority review.
  • Coverage during the 4-year transition applies only if the device is used according to FDA labeling and for the specific indication that got priority review.
  • Devices that the Secretary finds pose undue risk may not be covered.

• Device manufacturers

  • Can apply to CMS for “breakthrough device” designation (decided within 6 months).
  • If designated, their device would have a defined 4-year period during which Medicare coverage is possible under the bill’s terms.
  • For devices cleared via 510(k), the bill requires clinical data supporting clearance that may include Medicare beneficiaries.

• Hospitals and clinicians

  • Can bill Medicare for designated breakthrough devices used per FDA labeling during the transitional period.
  • May face CMS review if their billing for a device is an outlier (aberrant billing review).

• CMS and federal administrators

  • Must process designation applications, manage transitional coverage, perform NCDs on an accelerated schedule for these devices, and run billing/outlier reviews.
  • Receive dedicated funding to support these tasks.

• Taxpayers

  • The bill directs new appropriation funding to CMS and could affect Medicare spending if more new devices are covered during transition.

Expenses#

Estimated public cost: $10,000,000 per year for each fiscal year 2025 through 2030 is specifically appropriated to CMS’s Program Management Account.

• Direct appropriation: $10 million per year (FY2025–2030), available until spent, to carry out the bill’s changes.
• Possible added Medicare spending: Because devices designated as breakthrough may be covered during a 4-year transition, Medicare program spending could increase, but the bill does not provide an estimate.
• Administrative costs: CMS will need staff/time to review designation applications, make faster national coverage determinations, and perform aberrant-billing reviews. No separate cost estimate is provided for these activities.
• No other fee, fine, or dedicated offset is specified in the bill.

If you need a formal budget estimate or actuarial numbers, no such fiscal note is included in the bill text provided.

Proponents' View#

The bill appears intended to:

• Speed patient access to novel medical devices that the FDA has prioritized, by creating a predictable 4-year window for Medicare coverage while broader coverage reviews proceed.
• Give manufacturers a clear, time-limited pathway to have their devices considered for Medicare payment, with a required decision timeline (6 months to designate; accelerated NCD timing).
• Encourage inclusion of Medicare populations in clinical data (the bill asks that 510(k) clearances be based on clinical data that may include Medicare enrollees).
• Provide CMS modest, dedicated funding to handle increased workload related to designation, coverage decisions, and billing oversight.

Opponents' View#

One concern is that the bill leaves several practical questions unanswered and may increase costs or risks:

• The bill does not provide a fiscal estimate of how much Medicare spending could rise if more breakthrough devices become covered during the transition.
• It does not specify payment rates, billing codes, or detailed payment rules for devices covered under the transitional period, which could cause uncertainty for providers and payers.
• Allowing coverage during a transition might result in wider use of devices with more limited evidence of long-term outcomes; although the bill requires FDA labeling and a safety review, the standard for “undue risk” and how it will be applied is not fully detailed.
• Administrative burden on CMS could grow (designation decisions, faster NCDs, billing reviews), and the annual $10 million appropriation may or may not be adequate to cover that workload.
• The bill’s requirement that some 510(k) clearances be supported by clinical data “may” include Medicare enrollees, but it does not require such enrollment in every case; the impact on the evidence base for Medicare patients is unclear.

What is unclear:

• Exactly how Medicare payment will be handled for each device during the transitional period (payment method and rates).
• How frequently CMS will find devices present “undue risk” and how that review will be conducted in practice.
• Whether the $10 million per year is sufficient to carry out all delegated tasks.